Langenbeck's Archives of Surgery

, Volume 395, Issue 6, pp 597–605 | Cite as

Endotoxin elimination in sepsis: physiology and therapeutic application

  • Klaus Buttenschoen
  • Peter Radermacher
  • Hendrik Bracht
Overview

Abstract

Purpose

The present review summarizes key papers on the elimination of endotoxin in human.

Results

Lipopolysaccharides (LPS) are extremely strong stimulators of inflammatory reactions, act at very low concentrations, and are involved in the pathogenesis of sepsis and septic shock. Elimination of LPS is vital; therefore, therapeutic detoxification of LPS may offer new perspectives. Multiple mechanisms eliminate LPS in human comprising molecules that bind LPS and prevent it from signaling, enzymes that degrade and detoxify LPS, processes that inactivate LPS following uptake into the reticulo-endothelial system, and mechanisms of adaptation that modify target cells responding to LPS. These mechanisms are powerful and detoxification capacity adapts as required. Results of therapeutic interventions aiming at the removal of LPS by medication (immunoglobulins) or extracorporeal means are controversial. At least in part, animal experiments revealed increased survival. Human trials confirmed the positive effects on parameters of secondary importance, but not on morbidity or survival which was attributed to the heterogeneity of patients suffering from consequences of severe infectious diseases and sepsis.

Conclusion

The hypothesis of LPS-driven inflammatory processes remains very attractive. However, few therapeutic yet immature options have been developed to date.

Keywords

Lipopolysaccharide Elimination Detoxification Degradation Adsorber 

Notes

Acknowledgments

No funding was received for doing this overview. Klaus Buttenschoen, Peter Radermacher, and Hendrik Bracht are authors of the publication Eur Surg Res (2009) 43:53–60, “Efficacy of an Extracorporeal Endotoxin Adsorber System during Hyperdynamic Porcine Endotoxemia”. This study was supported by a research grant of Fresenius Company, Germany.

References

  1. 1.
    Greisman SE, Hornick RB (1969) Comparative pyrogenic reactivity of rabbit and man to bacterial endotoxin. Proc Soc Exp Biol Med 131:1154–1158PubMedGoogle Scholar
  2. 2.
    Bentala H, Verweij WR, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer DK, Poelstra K (2002) Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 18:561–566CrossRefPubMedGoogle Scholar
  3. 3.
    Buttenschoen K, Fathimani K, Carli Buttenschoen D (2010) Effect of major abdominal surgery on the host immune response to infection. Curr Opin Infect Dis 23:259–267CrossRefPubMedGoogle Scholar
  4. 4.
    Munford RS (2005) Detoxifying endotoxin: time, place and person. J Endotoxin Res 11:69–84PubMedGoogle Scholar
  5. 5.
    Fischer MB, Prodeus AP, Nicholson-Weller A, Ma M, Murrow J, Reid RR, Warren HB, Lage AL, Moore FD Jr, Rosen FS, Carroll MC (1997) Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J Immunol 159:976–982PubMedGoogle Scholar
  6. 6.
    Buttenschoen K, Berger D, Strecker W, Carli Buttenschoen D, Stenzel K, Pieper T, Beger HG (2000) Association of endotoxemia and production of antibodies against endotoxins following multiple injuries. J Trauma 48:918–923CrossRefPubMedGoogle Scholar
  7. 7.
    Gazzano-Santoro H, Meszaros K, Birr C, Carroll SF, Theofan G, Horwitz AH, Lim E, Aberle S, Kasler H, Parent JB (1994) Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and Gram-negative bacteria. Infect Immun 62:1185–1191PubMedGoogle Scholar
  8. 8.
    von der Mohlen MA, van Deventer SJ, Levi M, van den Ende B, Wedel NI, Nelson BJ, Friedmann N, Ten Cate JW (1995) Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23). Blood 85:3437–3443PubMedGoogle Scholar
  9. 9.
    Vesy CJ, Kitchens RL, Wolfbauer G, Albers JJ, Munford RS (2000) Lipopolysaccharide-binding protein and phospholipid transfer protein release lipopolysaccharides from Gram-negative bacterial membranes. Infect Immun 68:2410–2417CrossRefPubMedGoogle Scholar
  10. 10.
    Domingues MM, Castanho MA, Santos NC (2009) rBPI(21) promotes lipopolysaccharide aggregation and exerts its antimicrobial effects by (hemi)fusion of PG-containing membranes. PLoS ONE 4:e8385CrossRefPubMedGoogle Scholar
  11. 11.
    Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CR (1991) Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem 266:19490–19498PubMedGoogle Scholar
  12. 12.
    Weinrauch Y, Katz SS, Munford RS, Elsbach P, Weiss J (1999) Deacylation of purified lipopolysaccharides by cellular and extracellular components of a sterile rabbit peritoneal inflammatory exudate. Infect Immun 67:3376–3382PubMedGoogle Scholar
  13. 13.
    Feulner JA, Lu M, Shelton JM, Zhang M, Richardson JA, Munford RS (2004) Identification of acyloxyacyl hydrolase, a lipopolysaccharide-detoxifying enzyme, in the murine urinary tract. Infect Immun 72:3171–3178CrossRefPubMedGoogle Scholar
  14. 14.
    Verweij WR, Bentala H, Huizinga-Van der Vlag A, Miek vL-W, Kooi K, Meijer DK, Poelstra K (2004) Protection against an Escherichia coli-induced sepsis by alkaline phosphatase in mice. Shock 22:174–179CrossRefPubMedGoogle Scholar
  15. 15.
    Bol-Schoenmakers M, Fiechter D, Raaben W, Hassing I, Bleumink R, Kruijswijk D, Maijoor K, Tersteeg-Zijderveld M, Brands R, Pieters R (2010) Intestinal alkaline phosphatase contributes to the reduction of severe intestinal epithelial damage. Eur J Pharmacol 633:71–77CrossRefPubMedGoogle Scholar
  16. 16.
    Ge Y, Ezzell RM, Tompkins RG, Warren HS (1994) Cellular distribution of endotoxin after injection of chemically purified lipopolysaccharide differs from that after injection of live bacteria. J Infect Dis 169:95–104PubMedGoogle Scholar
  17. 17.
    Knolle PA, Gerken G (2000) Local control of the immune response in the liver. Immunol Rev 174:21–34CrossRefPubMedGoogle Scholar
  18. 18.
    Ruiter DJ, van der Meulen J, Brouwer A, Hummel MJ, Mauw BJ, van der Ploeg JC, Wisse E (1981) Uptake by liver cells of endotoxin following its intravenous injection. Lab Invest 45:38–45PubMedGoogle Scholar
  19. 19.
    Jackson GD, Dai Y, Sewell WA (2000) Bile mediates intestinal pathology in endotoxemia in rats. Infect Immun 68:4714–4719CrossRefPubMedGoogle Scholar
  20. 20.
    Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, Lembo A, Kalis C, Gumenscheimer M (2002) The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res 8:319–327PubMedGoogle Scholar
  21. 21.
    Satoh M, Ando S, Shinoda T, Yamazaki M (2008) Clearance of bacterial lipopolysaccharides and lipid A by the liver and the role of argininosuccinate synthase. Innate Immun 14:51–60CrossRefPubMedGoogle Scholar
  22. 22.
    Vreugdenhil AC, Rousseau CH, Hartung T, Greve JW, van’t V, Buurman WA (2003) Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol 170:1399–1405PubMedGoogle Scholar
  23. 23.
    Levels JH, Abraham PR, van den Ende A, van Deventer SJ (2001) Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun 69:2821–2828CrossRefPubMedGoogle Scholar
  24. 24.
    Diks SH, van Deventer SJ, Peppelenbosch MP (2001) Lipopolysaccharide recognition, internalisation, signalling and other cellular effects. J Endotoxin Res 7:335–348PubMedGoogle Scholar
  25. 25.
    Caron E, Hall A (1998) Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science 282:1717–1721CrossRefPubMedGoogle Scholar
  26. 26.
    Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, Aderem A (1999) The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401:811–815CrossRefPubMedGoogle Scholar
  27. 27.
    Kitchens RL, Munford RS (1998) CD14-dependent internalization of bacterial lipopolysaccharide (LPS) is strongly influenced by LPS aggregation but not by cellular responses to LPS. J Immunol 160:1920–1928PubMedGoogle Scholar
  28. 28.
    Bunnell E, Lynn M, Habet K, Neumann A, Perdomo CA, Friedhoff LT, Rogers SL, Parrillo JE (2000) A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit Care Med 28:2713–2720CrossRefPubMedGoogle Scholar
  29. 29.
    Jaber BL, Pereira BJ (1997) Extracorporeal adsorbent-based strategies in sepsis. Am J Kidney Dis 30:S44–S56CrossRefPubMedGoogle Scholar
  30. 30.
    Anspach FB (2001) Endotoxin removal by affinity sorbents. J Biochem Biophys Meth 49:665–681CrossRefPubMedGoogle Scholar
  31. 31.
    Srimal S, Surolia N, Balasubramanian S, Surolia A (1996) Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A. Biochem J 315(Pt 2):679–686PubMedGoogle Scholar
  32. 32.
    Kawatsu M, Wada J, Kitano M, Ogino E, Sakurai H, Furuyoshi S, Tani N (2006) Effects of a new extracorporeal system using CTR on mortality and inflammatory responses to bacterial toxin-induced multiple organ dysfunction syndrome in rabbits. Blood Purif 24:327–334CrossRefPubMedGoogle Scholar
  33. 33.
    Taniguchi T, Hirai F, Takemoto Y, Tsuda K, Yamamoto K, Inaba H, Sakurai H, Furuyoshi S, Tani N (2006) A novel adsorbent of circulating bacterial toxins and cytokines: the effect of direct hemoperfusion with CTR column for the treatment of experimental endotoxemia. Crit Care Med 34:800–806PubMedGoogle Scholar
  34. 34.
    Bracht H, Hauser B, Ivanyi Z, Asfar P, Ehrmann U, Brueckner UB, Georgieff M, Radermacher P, Buttenschoen K (2009) Efficacy of an extracorporeal endotoxin adsorber system during hyperdynamic porcine endotoxemia. Eur Surg Res 43:53–60CrossRefPubMedGoogle Scholar
  35. 35.
    Kojika M, Sato N, Yaegashi Y, Suzuki Y, Suzuki K, Nakae H, Endo S (2006) Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity. Ther Apher Dial 10:12–18CrossRefPubMedGoogle Scholar
  36. 36.
    Ebihara I, Nakamura T, Shimada N, Shoji H, Koide H (1998) Effect of hemoperfusion with polymyxin B-immobilized fiber on plasma endothelin-1 and endothelin-1 mRNA in monocytes from patients with sepsis. Am J Kidney Dis 32:953–961CrossRefPubMedGoogle Scholar
  37. 37.
    Blomquist S, Gustafsson V, Manolopoulos T, Pierre L (2009) Clinical experience with a novel endotoxin adsorbtion device in patients undergoing cardiac surgery. Perfusion 24:13–17CrossRefPubMedGoogle Scholar
  38. 38.
    Ullrich H, Jakob W, Frohlich D, Rothe G, Prasser C, Drobnik W, Taeger K, Meier-Hellmann A, Reinhart K, Zimmermann M, Schmitz G (2001) A new endotoxin adsorber: first clinical application. Ther Apher 5:326–334CrossRefPubMedGoogle Scholar
  39. 39.
    Reinhart K, Meier-Hellmann A, Beale R, Forst H, Boehm D, Willatts S, Rothe KF, Adolph M, Hoffmann JE, Boehme M, Bredle DL (2004) Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected Gram-negative sepsis. Crit Care Med 32:1662–1668CrossRefPubMedGoogle Scholar
  40. 40.
    Buttenschoen K, Kornmann M, Berger D, Leder G, Beger HG, Vasilescu C (2008) Endotoxemia and endotoxin tolerance in patients with ARDS. Langenbecks Arch Surg 393:473–478CrossRefPubMedGoogle Scholar
  41. 41.
    Nakamura T, Fujiwara N, Sato E, Kawagoe Y, Ueda Y, Yamada S, Koide H (2009) Effect of polymyxin B-immobilized fiber hemoperfusion on serum high mobility group box-1 protein levels and oxidative stress in patients with acute respiratory distress syndrome. ASAIO J 55:395–399CrossRefPubMedGoogle Scholar
  42. 42.
    Nakamura T, Yamagishi SI (2010) PEDF and septic shock. Curr Mol Med 10:312–316CrossRefPubMedGoogle Scholar
  43. 43.
    Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, Mehta S, Derzko A, Romaschin A (2004) Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC Study. J Infect Dis 190:527–534CrossRefPubMedGoogle Scholar
  44. 44.
    Yachamaneni S, Yushin G, Yeon SH, Gogotsi Y, Howell C, Sandeman S, Phillips G, Mikhalovsky S (2010) Mesoporous carbide-derived carbon for cytokine removal from blood plasma. Biomaterials 31:4789–4794CrossRefPubMedGoogle Scholar
  45. 45.
    Bertok L (2005) Radio-detoxified endotoxin activates natural immunity: a review. Pathophysiology 12:85–95CrossRefPubMedGoogle Scholar
  46. 46.
    Hurley JC, Levin J (1999) The relevance of endotoxin detection in sepsis. In: Brade H, Opal SM, Vogel SN, Morrison DC (eds) Endotoxin in health and disease. Marcel Dekker, New York, pp 841–854Google Scholar
  47. 47.
    Hurley JC (2003) Endotoxemia and Gram-negative bacteremia as predictors of outcome in sepsis: a meta-analysis using ROC curves. J Endotoxin Res 9:271–279PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Klaus Buttenschoen
    • 1
  • Peter Radermacher
    • 2
  • Hendrik Bracht
    • 2
  1. 1.Department of Surgery, Division of General SurgeryUniversity of AlbertaEdmontonCanada
  2. 2.Sektion Anästhesiologische Pathophysiologie und VerfahrensentwicklungUniversitätsklinik für AnästhesiologieUniversitätsklinikumGermany

Personalised recommendations